Companies › Mannkind
2 active drug programs in 6 registered trials: 4 Phase 2, 2 Phase 1; Respiratory, Neurology, Metabolic and endocrine, Psychiatry; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Insulin Human Insulin receptor agonist | INSR | Phase 2 | Type 1 Diabetes Mellitus; Alzheimer Disease; Type 2 Diabetes; Spinal Cord Injury … | Mar 2027 |
| Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07384052 | Insulin Human | Phase 1 | Spinal Cord Injury | Neurology | Dec 2026 |
| NCT05988632 | Insulin Human | Phase 1 | Alcohol Use Disorder | Psychiatry | Dec 2026 |
| NCT07224321 | Insulin Human | Phase 2 | Type 1 Diabetes Mellitus | Respiratory | Mar 2027 |
| NCT06072963 | Insulin Human | Phase 2 | Alzheimer Disease | Neurology | Dec 2027 |
| NCT07679893 | Nintedanib (MNKD-201) | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Dec 2027 |
| NCT07675499 | Insulin Human | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | May 2029 |
Cash and short-term investments of $97m on 2026-09-30; operating cash outflow about $78m a year; runway about 15 months at that burn, to Dec 2027; 2 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Rein Therapeutics aTyr Pharma Avalyn Pharma Arcturus Therapeutics Aspeya
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.